Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: The efficacy and safety of mepolizumab in patients with severe eosinophilic asthma has been evaluated in a global clinical trial programme. This post hoc analysis assesses the efficacy and safety of mepolizumab in Korean patients. Methods: Data from Korean patients in the Phase III, placebo-controlled, randomised DREAM (MEA112997/NCT01000506) and MENSA (MEA115588/ NCT01691521) studies were included. Patients ≥ 12 years old with severe eosinophilic asthma received mepolizumab (DREAM: 75, 250 or 750 mg intravenously [IV]; MENSA: 75 mg IV or 100 mg subcutaneously [SC]), or placebo every 4 weeks for 52 weeks (DREAM) or 32 weeks (MENSA). The primary outcome was the rate of clinically significant asthma exacerbations. Secondary outcomes included forced expiratory volume in 1 second (FEV1), Asthma Control Questionnaire (ACQ) and St George’s Respiratory Questionnaire (SGRQ) scores (MENSA only). Blood eosinophil counts (BEC) and safety were assessed throughout. Results: Reductions in the rate of clinically significant asthma exacerbations were observed with the approved (100 mg SC) and bioequivalent (75 mg IV) doses of mepolizumab in Korean patients who participated in DREAM and MENSA. In MENSA, trends for improvements from baseline at week 32 in pre-bronchodilator FEV1 (75 mg IV group), ACQ-5 and SGRQ scores (in both treatment groups) were seen versus placebo in Korean patients. Incidence of on-treatment adverse events was similar in Korean patients versus non-Korean patients as were observed reductions from baseline in BEC. Conclusions: Mepolizumab treatment provided clinical benefits for Korean patients with severe eosinophilic asthma; the safety profile is consistent with the overall population.
Abstract
Background/Aims: The efficacy and safety of mepolizumab in patients with severe eosinophilic asthma has been evaluated in a global clinical trial programme. This post hoc analysis assesses the efficacy and safety of mepolizumab in Korean patients. Methods: Data from Korean patients in the Phase III, placebo-controlled, randomised DREAM (MEA112997/NCT01000506) and MENSA (MEA115588/ NCT01691521) studies were included. Patients ≥ 12 years old with severe eosinophilic asthma received mepolizumab (DREAM: 75, 250 or 750 mg intravenously [IV]; MENSA: 75 mg IV or 100 mg subcutaneously [SC]), or placebo every 4 weeks for 52 weeks (DREAM) or 32 weeks (MENSA). The primary outcome was the rate of clinically significant asthma exacerbations. Secondary outcomes included forced expiratory volume in 1 second (FEV1), Asthma Control Questionnaire (ACQ) and St George’s Respiratory Questionnaire (SGRQ) scores (MENSA only). Blood eosinophil counts (BEC) and safety were assessed throughout. Results: Reductions in the rate of clinically significant asthma exacerbations were observed with the approved (100 mg SC) and bioequivalent (75 mg IV) doses of mepolizumab in Korean patients who participated in DREAM and MENSA. In MENSA, trends for improvements from baseline at week 32 in pre-bronchodilator FEV1 (75 mg IV group), ACQ-5 and SGRQ scores (in both treatment groups) were seen versus placebo in Korean patients. Incidence of on-treatment adverse events was similar in Korean patients versus non-Korean patients as were observed reductions from baseline in BEC. Conclusions: Mepolizumab treatment provided clinical benefits for Korean patients with severe eosinophilic asthma; the safety profile is consistent with the overall population.
참고문헌 (20)
- 유광하, "Burden of Respiratory Disease in Korea: An Observational Study on Allergic Rhinitis, Asthma, COPD, and Rhinosinusitis", Allergy, Asthma & Immunology Research, 8(6), pp.527~534 (2016), 대한천식알레르기학회
- Chung KF, "International ERS", ATS guidelines on definition, evaluation and treatment of severe asthma, 2014, pp.43, 343~373
- O’Byrne PM, "Severe asthma : future treatments", Clin Exp Allergy, 42, pp.706~711 (2012)
- Merritt L. Fajt, "Development of New Therapies for Severe Asthma", Allergy, Asthma & Immunology Research, 9(1), pp.3~14 (2017), 대한천식알레르기학회
- 김민혜, "Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry", Allergy, Asthma & Immunology Research, 11(1), pp.43~54 (2019), 대한천식알레르기학회
- Wenzel SE, "Asthma : defining of the persistent adult phenotypes", Lancet, 368, pp.804~813 (2006)
- ten Brinke A, ""Refractory"eosinophilic airway inflammation in severe asthma : effect of parenteral corticosteroids", Am J Respir Crit Care Med, 170, pp.601~605 (2004)
- Yancey SW, "Biomarkers for severe eosinophilic asthma", J Allergy Clin Immunol, 140, pp.1509~1518 (2017)
- "Prescribing information" (2019)[URL]
- Ortega HG, "Mepolizumab treatment in patients with severe eosinophilic asthma", N Engl J Med, 371, pp.1198~1207 (2014)
- Pavord ID, "Mepolizumab for severe eosinophilic asthma(DREAM) : a multicentre, double-blind, placebo-controlled trial", Lancet, 380, pp.651~659 (2012)
- Chupp GL, "Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma(MUSCA) : a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial", Lancet Respir Med, 5, pp.390~400 (2017)
- Chiba K, "A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed?", J Clin Pharmacol, 54, pp.483~494 (2014)
- Ramamoorthy A, "Racial", ethnic differences in drug disposition and response : review of recently approved drugs, 2015, pp.97, 263~273
- "Clinical study report 2014" (2014)[URL]
- Wechsler ME, "Impact of race on asthma treatment failures in the asthma clinical research network", Am J Respir Crit Care Med, 184, pp.1247~1253 (2011)
- Baffi CW, "Asthma and obesity : mechanisms and clinical implications", Asthma Res Pract, 1, pp.1~ (2015)
- WHO Expert Consultation, "Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies", Lancet, 363, pp.157~163 (2004)
- Shimoda T, "Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma", Allergol Int, 66, pp.445~451 (2017)
- Kurosawa M, "Prospective open-label study of 48-week subcutaneous administration of mepolizumab in Japanese patients with severe eosinophilic asthma", J Investig Allergol Clin Immunol, 29, pp.40~45 (2019)